专业研究机构Frost Sullivan关于contract research and manufacturing organization（CRAMS）即医药行业合同研究组织和合同生产组织的研究报告，去年在纽交所上市的无锡药明康德就属于CRO，有兴趣的朋友可以看一下！

 

 

Introduction 
Over the last decade outsourcing has become an important strategic issue for pharmaceutical
companies due to declining R&D productivity, increased generic competition, blockbuster drugs
going off-patent, rising drug development costs and fewer new drugs discoveries. Under pressure
to protect their margins, innovators are outsourcing non-core activities like manufacturing of
intermediates and APIs to low cost destinations like India, which is likely to gain momentum over
the next Decade. India currently accounts for a miniscule proportion of the US$ 27 billion global
outsourcing industry and is set to capitalize on the mega opportunity.
 
Global Outsourcing Scenario
Current market for outsourcing in the Pharmaceutical and Biotechnology Industry is valued at
$100 billion in 2006 growing at around 10.8 percent to reach $168 billion by 2009.
API Manufacturing is the largest contributor to outsourcing market with a 55 percent share.
Clinical Research with a 35 percent share of the market is the second largest segment
contributing to more than one-fourth of the revenues in this industry followed closely by Drug
discovery and Dosage form Development at 25 percent and 20 percent, respectively.